Adjuvant CMF (cyclophosphamide, methotrexate, fluorouracil) in breast cancer. Is it cost-effective?

被引：0
|
作者：
Norum, J [1 ]
机构：
[1] Univ Tromso Hosp, Dept Oncol, N-9012 Tromso, Norway
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81319-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
899
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [21] ADRIAMYCIN, VINCRISTIN, CYCLOPHOSPHAMIDE AND 5-FLUOROURACIL (AVCF) ADJUVANT TREATMENT OF BREAST-CANCER COMPARED TO TREATMENT WITH CYCLOPHOPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF)
    MATHE, G
    MISSET, JL
    PLAGNE, R
    BELPOMME, D
    LEMEVEL, B
    GUERRIN, J
    FUMOLEAU, P
    METZ, R
    DELGADO, M
    DEVASSAL, F
    ERIGUCHI, M
    SCHNEIDER, M
    REIZENSTEIN, P
    BREAST CANCER RESEARCH AND TREATMENT, 1985, 6 (02) : 168 - 168
  • [22] A RANDOMIZED ADJUVANT STUDY OF CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL (CMF) WITH AND WITHOUT RADIATION-THERAPY (RT) FOR STAGE-II BREAST-CANCER
    MUSS, H
    COOPER, MR
    FERREE, C
    RICHARDS, F
    STUART, J
    WHITE, D
    RHYNE, L
    SPURR, C
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 399 - 399
  • [23] Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’
    Romano Demicheli
    Rosalba Miceli
    Cristina Brambilla
    Laura Ferrari
    Angela Moliterni
    Milvia Zambetti
    Pinuccia Valagussa
    Gianni Bonadonna
    Breast Cancer Research and Treatment, 1999, 53 : 209 - 215
  • [24] Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'
    Demicheli, R
    Miceli, R
    Brambilla, C
    Ferrari, L
    Moliterni, A
    Zambetti, M
    Valagussa, P
    Bonadonna, G
    BREAST CANCER RESEARCH AND TREATMENT, 1999, 53 (03) : 209 - 215
  • [25] Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer
    Bonadonna, Gianni
    Valagussa, Pinuccia
    Veronesi, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) : 342 - 344
  • [26] Erratum to: Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer
    A. Messori
    P. Becagli
    S. Trippoli
    E. Tendi
    European Journal of Clinical Pharmacology, 1997, 51 : 427 - 427
  • [27] The comparative study of adjuvant chemotherapy of breast cancer with cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus doxorubicin, cyclophosphamide (AC). First results of national cooperative study
    Pribylova, O
    Petruzelka, L
    Fischer, J
    Bustova, I
    Siffnerova, H
    Kuta, M
    Muller, V
    Hacklova, M
    Machacek, J
    Kohoutek, M
    Vodvarka, P
    Kysela, T
    Tajblova, J
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 811 - 815
  • [28] Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy (CMF) and radiotherapy for breast carcinoma
    Livi, L.
    Meattini, O.
    Fondelli, F.
    Ci Cosmo, D.
    Paoletti, L.
    Biti, G.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S282 - S282
  • [29] Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer.
    Batey, MA
    Wright, JG
    Simmonds, D
    Proctor, M
    Chapman, F
    Fishwick, K
    Azzabi, A
    Newell, DR
    Lind, MJ
    Calvert, AH
    Boddy, AV
    BRITISH JOURNAL OF CANCER, 1999, 80 : 93 - 93
  • [30] Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer
    Marty, ME
    Coombes, RC
    Peckitt, C
    López, FRP
    Tres, A
    Morvan, F
    Tubiana-Mathieu, N
    Espié, M
    Bliss, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 25S - 25S
12345